• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Warrant (NQ:TVGNW)

0.0440 -0.0135 (-23.48%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Bio Holdings Inc. - Warrant

< Previous 1 2 3 4 5 Next >
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
October 11, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
October 08, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
September 24, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
August 22, 2024
From Tevogen Bio Inc
Via GlobeNewswire
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
August 14, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
August 09, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
July 11, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
July 10, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
June 26, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
July 08, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
June 25, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
June 18, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Set to Join Russell 3000® Index
June 12, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 11, 2024
From Tevogen Bio Inc
Via GlobeNewswire
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
June 07, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
June 06, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 06, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 16, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
April 26, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
April 03, 2024
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 28, 2024
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap